前立腺癌患者における血清γ-セミノブロテインの検討

Abstract

γ-セミノプロテイン(γ-Sm)は前立腺癌の腫瘍マーカーとして注目を集めている.そこで, 未治療前立腺癌患者および前立腺肥大症患者の血清γ-Smを測定し, 従来よりのマーカーである前立腺性酸性フォスファターゼ(PAP)と比較検討した.その結果, 1) γ-Sm値は前立腺癌症例群と前立腺肥大症症候群との間に有意差を認めた.2)前立腺癌症例におけるγ-Sm値はstageが進むにつれて有意に上昇した.3) γ-Sm値の非癌域値上限は5.0 ng/mlにするのが適応である.4)前立腺癌, とくに早期癌においてγ-SmはPAPに比べ, より有用なマーカーであることが示唆された

The level of serum gamma-seminoprotein (gamma-Sm) was measured by enzyme immunoassay in 62 patients with untreated prostatic cancer and 89 patients with benign prostatic hypertrophy histologically diagnosed to assess the clinical usefulness as a tumor marker. The level of serum prostatic acid phosphatase (PAP) was also measured by radioimmunoassay in these patients simultaneously. Serum gamma-Sm levels in prostatic cancer were significantly higher than in benign prostatic hypertrophy. There was a tendency for serum gamma-Sm levels in prostatic cancer to increase with statistically significant difference as the stage progressed. A gamma-Sm level of over 5.0 ng/ml was considered to be positive. The positive rate of gamma-Sm was 56.5% in prostatic cancer (stage A.B: 32.3%, stage C: 75.0%, stage D: 90.9%) and 19.1% in benign prostatic hypertrophy. In stage A.B cases, the positive rate of gamma-Sm was higher than that of PAP. Therefore, the measurement of gamma-Sm is considered to be useful in the diagnosis of early prostatic cancer.